HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Admission plasma visfatin level strongly correlates with hematoma growth and early neurologic deterioration in patients with acute spontaneous basal ganglia hemorrhage.

AbstractBACKGROUND:
Visfatin, a proinflammatory mediator, has been associated with poor clinical outcomes after acute brain injury. The present study is designed to investigate the potential association between plasma visfatin levels and the risk of hematoma growth (HG) and early neurologic deterioration (END) after intracerebral hemorrhage.
METHODS:
There were 85 patients as cases who presented with first-time hemorrhagic stroke that were assessed within 6h after the incident. The control group consisted of 85 healthy volunteers. HG was defined as hematoma enlargement >33% at 24h. END was defined as an increase of ≥ 4 points in National Institute of Health Stroke Scale score at 24h from symptoms onset. Plasma visfatin levels were determined using enzyme immunoassay.
RESULTS:
Plasma visfatin levels were significantly higher in patients compared to controls. Plasma visfatin level emerged as an independent predictor of HG [odds ratio (OR), 1.154; 95% confidence interval (CI), 1.046-3.108; P=0.009] and END (OR, 1.195; 95% CI, 1.073-3.516; P=0.005). For predicting HG, area under curve (AUC) of plasma visfatin level (0.814; 95% CI: 0.715-0.890) was similar to that of hematoma volume (0.839; 95% CI, 0.743-0.909) (P=0.703). For predicting END, AUC of plasma visfatin level (0.828; 95% CI: 0.730-0.901) was similar to that of hematoma volume (0.863; 95% CI, 0.771-0.928) (P=0.605). Visfatin did not improve AUC of hematoma volume for predicting HG and END (both P>0.05).
CONCLUSION:
Plasma visfatin level represents a novel biomarker for predicting HG and END.
AuthorsShui-Jun Gu, Hong-Fei Xuan, Ming Lu, Xin-Zhi Chen, Wei-Feng Dong, Xiao-Feng Yan, Yun Si, Guo-Liang Gao, Dian-Xiang Hu, Jian-Qing Miao
JournalClinica chimica acta; international journal of clinical chemistry (Clin Chim Acta) Vol. 425 Pg. 85-9 (Oct 21 2013) ISSN: 1873-3492 [Electronic] Netherlands
PMID23916712 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2013 Elsevier B.V. All rights reserved.
Chemical References
  • Biomarkers
  • Cytokines
  • Nicotinamide Phosphoribosyltransferase
  • nicotinamide phosphoribosyltransferase, human
Topics
  • Aged
  • Area Under Curve
  • Basal Ganglia Hemorrhage (blood, diagnosis, physiopathology)
  • Biomarkers (blood)
  • Case-Control Studies
  • Cognitive Dysfunction (blood, diagnosis, physiopathology)
  • Cytokines (blood, genetics)
  • Female
  • Gene Expression
  • Hematoma (blood, diagnosis, physiopathology)
  • Hospitalization
  • Humans
  • Male
  • Middle Aged
  • Nicotinamide Phosphoribosyltransferase (blood, genetics)
  • Prognosis
  • ROC Curve
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: